A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles

Alzheimer's Research and Therapy

Volumn 6, Issue 3, 2014, Pages

  Lehmann, Sylvain ^a   Dumurgier, Julien ^b   Schraen, Susanna ^c   Wallon, David ^d   Blanc, Frédéric ^e,f   Magnin, Eloi ^g   Bombois, Stéphanie ^c   Bousiges, Olivier ^e,h,i   Campion, Dominique ^d   Cretin, Benjamin ^e   Delaby, Constance ^a   Hannequin, Didier ^d   Jung, Barbara ^e   Hugon, Jacques ^b   Laplanche, Jean Louis ^b   Miguet Alfonsi, Carole ^g   Peoc'H, Katell ^b   Philippi, Nathalie ^e,f   Quillard Muraine, Muriel ^d   Sablonnière, Bernard ^c   Touchon, Jacques ^a   Vercruysse, Olivier ^c   Paquet, Claire ^b   Pasquier, Florence ^c   Gabelle, Audrey ^a   more..

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b HÔPITAL FERNAND WIDAL   (France)

^c UNIV LILLE   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f UNIVERSITÉ DE STRASBOURG   (France)

^g UNIVERSITY HOSPITAL OF BESANÇON   (France)

^h HÔPITAL DE HAUTEPIERRE   (France)

ⁱ CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PHOSPHOPROTEIN; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL PRACTICE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

EID: 84904877099     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt267     Document Type: Article

References (32)

1. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P, Lancet Neurol 2007 6 734 746 (Pubitemid 47058377)
2. Revision of the criteria for Alzheimer's disease: a symposium. DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM, Gold M, Miller DS, Morimoto BH, Khachaturian AS, Mohs RC, Alzheimers Dement 2011 7 1 e12
3. Changing concepts of Alzheimer disease. McKhann GM, JAMA 2011 305 2458 2459
4. White matter changes on CT and MRI: an overview of visual rating scales: European Task Force on Age-Related White Matter Changes. Scheltens P, Erkinjunti T, Leys D, Wahlund LO, Inzitari D, del Ser T, Pasquier F, Barkhof F, Mantyla R, Bowler J, Wallin A, Ghika J, Fazekas F, Pantoni L, Eur Neurol 1998 39 80 89 (Pubitemid 28069798)
5. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Brain 2011 133 3336 3348
6. Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. Mouton-Liger F, Wallon D, Troussiere AC, Yatimi R, Dumurgier J, Magnin E, de la Sayette V, Duron E, Philippi N, Beaufils E, Gabelle A, Croisile B, Robert P, Pasquier F, Hannequin D, Hugon J, Paquet C, J Neurol 2014 261 144 151
7. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, Peoc'h K, Schraen S, Buee L, Pasquier F, Hugon J, Touchon J, Lehmann S, J Alzheimers Dis 2013 34 297 305
8. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K, Arch Neurol 2001 58 373 379 (Pubitemid 32217453)
9. Alzheimer's disease. Blennow K, de Leon MJ, Zetterberg H, Lancet 2006 368 387 403 (Pubitemid 44108123)
10. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ, Acta Neuropathol 2011 121 597 609
11. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T, Arch Neurol 2009 66 382 389
12. Biomarkers of Alzheimer's disease: the present and the future. Lehmann S, Delaby C, Touchon J, Hirtz C, Gabelle A, Rev Neurol (Paris) 2013 169 719 723
13. Clinical proteomics of the cerebrospinal fluid: towards the discovery of new biomarkers. Roche S, Gabelle A, Lehmann S, Proteomics 2008 2 428 436 (Pubitemid 351425370)
14. Genome-wide analysis of genetic loci associated with Alzheimer disease. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, et al. JAMA 2010 303 1832 1840
15. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K, Int J Alzheimers Dis 2010 doi:10.4061/2010/986310
16. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, Elmoualij B, Schraen S, Moreaud O, Gabelle A, Thouvenot E, Thomas-Anterion C, Touchon J, Krolak-Salmon P, Kovacs GG, Coudreuse A, Quadrio I, Lehmann S, J Alzheimers Dis 2012 31 13 20
17. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J, Clin Chem 2006 52 332 334 (Pubitemid 43185505)
18. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Saez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C, Biomark Med 2012 6 419 430
19. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, et al. Alzheimers Dement 2011 7 386 395
20. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, Dorey A, Dumurgier J, Hirtz C, Krolak-Salmon P, Laplanche JL, Moreaud O, Peoc'h K, Rouaud O, Sablonniere B, Thouvenot E, Touchon J, Vercruysse O, Hugon J, Gabelle A, Pasquier F, Perret-Liaudet A, Alzheimers Dement 2013 doi:10.1016/j.jalz.2013. 06.008
21. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H, Neurology 1999 52 1555 1562 (Pubitemid 29220627)
22. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. de Jong D, Jansen RW, Kremer BP, Verbeek MM, J Gerontol A Biol Sci Med Sci 2006 61 755 758 (Pubitemid 44148364)
23. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM, Neurology 2012 78 47 54
24. A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. Spies PE, Claassen JA, Peer PG, Blankenstein MA, Teunissen CE, Scheltens P, van der Flier WM, Olde Rikkert MG, Verbeek MM, Alzheimers Dement 2013 9 262 268
25. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL, Peoc'h K, Schraen S, Pasquier F, Touchon J, Hugon J, Lehmann S, Gabelle A, Alzheimers Dement 2013 9 406 413
26. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 (Pubitemid 14076461)
27. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, El Moualij B, Schraen S, Moreaud O, Gabelle A, Thouvenot E, Thomas-Anterion C, Touchon J, Krolak-Salmon P, Kovacs GG, Coudreuse A, Quadrio I, Lehmann S, Clin Chem 2012 58 787 789
28. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS, Stat Med 2008 27 157 172 discussion, 207-112 (Pubitemid 351193639)
29. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Blennow K, Hampel H, Weiner M, Zetterberg H, Nat Rev Neurol 2010 6 131 144
30. The Clinical Dementia Rating (CDR): current version and scoring rules. Morris JC, Neurology 1993 43 2412 2414 (Pubitemid 23346995)
31. Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. Scheltens P, Pasquier F, Weerts JG, Barkhof F, Leys D, Eur Neurol 1997 37 95 99 (Pubitemid 27077809)
32. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall AE, Carter SF, Scholl M, Choo IH, Nordberg A, Scheltens P, Frisoni GB, Neurology 2013 80 1048 1056